Notícias

AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.

Moby summary of Recursion Pharmaceuticals, Inc.'s Q2 2026 earnings call

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense guidance to $375 million and reaffirming expectations for an operating runway through early 2028. The

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.70% and -46.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Najat Khan: Good morning, everyone, and thank you for joining us. First, we're focusing on signal over noise, generating proof and proof points across our both wholly owned programs and our partner programs with the goal to showcase where AI can truly make a difference in creating value.

Recursion Pharmaceuticals (NASDAQ:RXRX) leadership used its latest earnings call to emphasize a sharper focus on translating artificial intelligence-enabled discovery into clinical and partnership “proof points,” while maintaining what it described as tighter financial discipline. CEO and President

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +25.42% and -60.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?